

ERRATUM

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Filip Van den Bosch · Andrew J. K. Ostor · Siegfried Wassenberg ·
Naijun Chen · Chen Wang · Vishvas Garg · Jasmina Kalabic

Published online: May 4, 2017
© The Author(s) 2017. This article is an open access publication

Erratum to: Rheumatol Ther
DOI 10.1007/s40744-017-0061-7

In the original publication, ADA treatment values mentioned in the results section, under the heading ‘Study Outcomes’ were published incorrectly.

The correct text should read “Additionally, compared to PSP users, PSP non-users had significantly lower percentage of patients that started at PAM-13 level 4 at baseline and remained at level 4 until week 78 of ADA treatment (52.4% vs 28.9%, $p = 0.001$)”.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The online version of the original article can be found under doi:[10.1007/s40744-017-0061-7](https://doi.org/10.1007/s40744-017-0061-7).

F. Van den Bosch (✉)
Ghent University Hospital and VIB Center for
Inflammation Research, Ghent, Belgium
e-mail: filip.vandenbosch@ugent.be

A. J. K. Ostor
Addenbrooke’s Hospital, Cambridge, UK

S. Wassenberg
Rheumazentrum, Ratingen, Germany

N. Chen · C. Wang · V. Garg
AbbVie Inc., North Chicago, IL, USA

J. Kalabic
AbbVie Deutschland GmbH & Co. KG,
Ludwigshafen, Germany